Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07220629 · ClinicalTrials.gov registry record · Phase 2
Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2)
A Phase 2 study of Obesity, sponsored by NodThera Limited.
- Active
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 10
- Study locations
NCT07220629: Active Phase 2 study of Obesity, sponsored by NodThera Limited.
NCT07220629 is a Phase 2 study of Obesity that is active but no longer recruiting, run by NodThera Limited. The registered enrollment target is 80 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (90% lower). The trial reports 10 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07220629, a Phase 2 study of Obesity, is active but no longer recruiting, sponsored by NodThera Limited.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 10
- Study locations
Study Summary
A Phase 2a randomized, double-blind, placebo-controlled, parallel-group, multicenter study to explore the safety and efficacy of NT-0796 as an adjunct to semaglutide in participants with obesity over a 6 months treatment period.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG NT-0796
Study Locations (10)
Florida
- Investigative Site - Cooper City
- Investigative Site - Hialeah
- Investigative Site - Jacksonville
- Investigative Site - Miami
Arizona
- Investigative Site - Mesa
Louisiana
- Investigative Site - Marrero
Ohio
- Investigative Site - Columbus
Texas
- Investigative Site - Seabrook
Utah
- Investigative Site - Salt Lake City
Virginia
- Investigative Site - Manassas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2025-10-02 |
| Est. Completion | 2026-06-01 |
| Phase | Phase 2 |
What the registry record for NCT07220629 still lists
NCT07220629 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07220629 lists 10 locations in 7 states (Florida, Arizona, Louisiana).
Frequently Asked Questions
What is clinical trial NCT07220629 about?
NCT07220629 is a clinical study titled "Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2)". A Phase 2a randomized, double-blind, placebo-controlled, parallel-group, multicenter study to explore the safety and efficacy of NT-0796 as an adjunct to semaglutide in participants with obesity over a 6 months treatment period.
What is the current status of trial NCT07220629?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2025-10-02. Estimated completion is 2026-06-01.
What conditions does trial NCT07220629 study?
This clinical trial studies the following conditions: Obesity.
What interventions are being tested in trial NCT07220629?
The interventions under investigation include: Placebo (DRUG), NT-0796 (DRUG).
Who is sponsoring clinical trial NCT07220629?
This trial is sponsored by NodThera Limited, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07220629 being conducted?
This trial has 10 study locations across Arizona, Florida, Louisiana, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07220629's enrollment target sits among peer trials
80 546th of 1053 higher than 498 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Convergent Mechanisms Underlying Reprometabolic Syndrome in Women
RECRUITING · Phase 2
-
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
RECRUITING · Phase 2
-
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
RECRUITING · Phase 2
-
Pharmacological and Behavioral Treatment After Bariatric Surgery
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI